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INTRODUCTION
Rheumatoid arthritis (RA) is a common human autoim-
mune disease with a prevalence of about 1% throughout the
world. It is discrete from osteoarthritis (OA) in terms of its
pathological cause although both arthritic diseases mainly
affect the joint. While there has been a progress in defining
its etiology and pathogenesis, its molecular mechanism in
pathology is still incompletely understood (1). 
Rheumatoid arthritis is characterized by chronic inflam-
mation at the synovial joint and infiltration by blood-derived
cells, memory T cells, macrophages, and plasma cells, all of
which show signs of hyper-activation of immune responses
(2, 3). Generally, autoimmune diseases including RA are trig-
gered by the immune response against own proteins leading
to severe inflammation. In RA, such inflammation causes
the cartilage destruction through the direct invasion of an
inflammatory mass, called pannus. It is composed predomi-
nantly of macrophage and fibroblasts that secrete proteases
and enzymes that can degrade the surrounding matrix and
cartilage (4). 
Several candidate antigens in RA such as type II collagen,
glucose-6-phosphate isomerase and human chondrocyte gly-
coprotein 39 have been evaluated from studies to figure out
how these molecules trigger to initiate the hyper-activation
of immune response leading to RA in vivo or in vitro (5-7).
However, only small subsets of RA patients exhibit immune
response to these antigens, and no correlation in disease dura-
tion, activity or severity among patients has been observed.
Therefore, identification of new candidate autoantigen pro-
teins binding to antibodies obtained from RA patients’ syn-
ovial fluid might give some insights into understanding the
molecular mechanism during RA pathogenesis. 
To identify new RA-specific proteins from patients’ synovi-
um or synovial fluid, we applied several different methods;
two-dimensional gel electrophoresis, antibody affinity purifi-
cation, and mass spectrometry. Here we report some proteins
responding to RA antibodies or being specifically expressed
in RA tissues.
MATERIALS AND METHODS
Materials
Human synovial fluids were obtained from the swollen knee
of Korean RA patients (9 males and 16 females, average age:
50 yr) using syringe at the Gyeongsang National University
Hospital during 2002-2003. RA (two females and a male,
average age: 60 yr) or OA (15 females and 5 males, average
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Disease-specific Proteins from Rheumatoid Arthritis Patients
Rheumatoid arthritis (RA) is a chronic inflammatiory disease that mainly destroys
cartilages or bones at the joints. This inflammatory disorder is initiated by self-attack
using own immune system, but the detail of pathological mechanism is unclear. Fea-
tures of autoantigens leading to autoimmune disease are also under veil although
several candidates including type II collagen have been suggested to play a role in
pathogenesis. In this report, we tried to identify proteins responding to antibodies
purified from RA patients and screen proteins up-regulated or down-regulated in
RA using proteomic approach. Fibronectin, semaphorin 7A precursor, growth fac-
tor binding protein 7 (GRB7), and immunoglobulin  chain were specifically asso-
ciated with antibodies isolated from RA synovial fluids. In addition, some metabolic
proteins such as adipocyte fatty acid binding protein, galectin-1 and apolipoprotein
A1 precursor were overexpressed in RA synovium. Also, expression of peroxiredox-
in 2 was up-regulated in RA. On the contrary, expression of vimentin was severely
suppressed in RA synoviocytes. Such findings might give some insights into under-
standing of pathological mechanism in RA.
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age: 67 yr) synovial tissues were obtained during the knee
operation after obtaining informed consents of patients at the
same institute for proteomic analysis. These patients were
diagnosed as RA by a clinical specialist in the basis of RA
clinical classification criteria (1987 ACR criteria). In addition,
the joint area of these patients was erosive by radiography
detection.
Purification of autoantibodies from synovial fluids  
Synovial fluids were diluted 3 folds with binding buffer
(10 mM Tris, pH 7.5) and applied to the 1 mL ImmunoPure
Plus Protein A Column (PIERCE, Rockford, IL, U.S.A.) pre-
equilibrated with 5 column volumes of the IgG binding buffer.
The column was washed with 10-15 column volumes of the
binding buffer. The bound IgG was eluted with 3-5 column
volumes of the elution buffer (0.1 M glycine buffer, pH 2-3).
The pooled protein fractions were immediately adjusted to
a physiological pH by the addition of a suitable, more con-
centrated buffer (1.0 M Tris, pH 7.5, 100  L of the buffer to
1 mL of sample). The eluted immunoglobulins were dialyzed
with 1×PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4). The concentration of purified
IgG was estimated using a commercial Bradford reagent (Bio-
Rad, Hercules, CA, U.S.A.). Commercial IgG (1.4  g/ L) was
used as a standard. 
Western blot
Total cell proteins derived from tissue or cells were separat-
ed on a SDS-gel electrophoresis or two-dimensional gel elec-
trophoresis and subsequently transferred to the nitrocellulose
membrane using a Trans-Blot SD Semi-dry transfer cell (Bio-
Rad) for 15-30 min at 15 V. SDS, acrylamide, methylene-
bisacrylamide, TEMED, ammonium persulfate, DTT, urea,
Tris, glycine, and glycerol, were purchased from Bio-Rad or
USB (Cleveland, OH, U.S.A.). Silver nitrate, Coomassie Bril-
liant Blue G-250, iodoacetamide, and -cyano-4-hydroxycin-
namic acid were from Sigma (St. Louis, MO, U.S.A.). The
membrane was blocked for 1 hr at room temperature in 5%
skim milk/TBST (25 mM Tris-HCl, pH 7.4, 137 mM NaCl,
2.7 mM KCl, and 0.1% Tween 20) and incubated with pri-
mary antibodies isolated from RA patients for 2 hr at room
temperature (1:100 in 5% skim milk/TBST). After wash for
30 min with TBST three times, the membrane was incubat-
ed with anti-human rabbit IgG (Santa Craz Biotechnology,
Santa Cruz, CA, U.S.A.) conjugated with HRP for 1 hr (1:
1,000 in 5% skim milk/TBST). Proteins were detected with
an enhanced chemiluminescence system (ECL, Amersham,
Buckinghamshire, U.K.) after wash with TBST three times. 
Coupling of purified IgG to CNBr-activated Sepharose 4B
One CNBr-linked Sepharose 4B (Pharmacia Biotech, Upp-
sala, Sweden) was swollen in 1 mM HCl for 15 min, and was-
hed with 40 mL of 1 mM HCl for 5 min five times, and then
changed twice with 5 mL coupling buffer (0.1 M NaHCO3,
pH 8.3). The gel was mixed with 10 mL coupling buffer con-
taining 10 mg purified IgG, and the mixture was rotated to
end-over-end for 2 hr at room temperature. After centrifuga-
tion at 2,000 rpm for 2 min, excess ligands were washed out
with at least 5 gel volumes of coupling buffer, and then any
remaining active groups was blocked with 0.1 M Tris (pH 8.0).
Ab-affinity purification
50  L of purified IgG coupled to CNBr-activated Sepharose
4B was used for this affinity isolation experiment. Protein mix-
tures obtained from OA or RA synvium was added to IgG-
coupled resins equilibrated with binding buffer (Tris, pH 7.5,
150 mM NaCl ) and incubated at 4℃ for 2 hr. After spin,
the resins were washed with the binding buffer twice. Proteins
bound to IgG were eluted by the addition of SDS-sample
buffer and separated by a 10% SDS-PAGE after boiling. 
Two-dimensional gel electrophoresis and matrix-assisted
laser desorption/ionization-time of flight (MALDI-TOF)
mass spectrometry
Frozen synovium tissues (500-600 mg) were washed with
PBS buffer to remove cell debris and blood and homogenized
in 20 mL lysis buffer (8 M urea, 2% CHAPS, ampholytes,
and 10% protease inhibitor cocktail). The protein solution
was clarified by Beckman TL-100 table-top ultracentrifuge
at 100,000 rpm at 4℃for 10 min. The collected supernatant
was stored at -70℃ until use. IPG strips of pH 3-10 and 4-
7 were purchased from Bio-Rad (ReadyStrip, 0.53170 mm;
Hercules, CA, U.S.A.). Bio-Lyte (pH 3-10) was from Bio-Rad.
The general methods for two-dimensional gel electrophoresis
and MALDI-TOF mass spectrometry were described in our
previous reports (8-10). Proteins were identified by peptide
mass fingerprinting with a search program MS-FIT (http://
prospector.ucsf.edu/ucsfhtml 3.4/msfit.htm).
RESULTS
High molecular weight proteins respond to antibodies
isolated from RA patients 
We here assumed most antibodies in the synovial fluid of
patients with severe RA are auto-reactive because autoanti-
bodis reacting with local synovial components are very cru-
cial for the pathological process of RA. Local synovial fluids
were collected from Korean RA’s patients, and total antibod-
ies in synovial fluids were purified using Protein-A affinity
chromatography. Total twenty different antibodies have been
independently isolated from RA patients (average age: 50 yr),480 C.W. Kim, E.H. Cho, Y.J. Lee, et al.
and all antibodies were purified to the near homogeneity (data
not shown). Two of them were shown in Fig. 1A.
These purified antibodies were used for a primary antibody
in blotting with total cellular proteins derived from RA syn-
ovium tissue and separated on a SDS-gel electrophoresis or
two-dimensional gel electrophoresis. Some proteins with high
molecular weight (over 100 kDa, indicated by arrows) were
reacted to most RA’s antibodies (Fig. 1B, lane 1-8). In addi-
tion, we detected not only heavy chains and light chains of
immunoglobulins but also some proteins placed between
heavy chain and light chain of immunoglobulin (Fig. 1B).
Furthermore, we applied the 2-DE gel blot method to detect
and isolate antigens using a RA antibody (marked as asterisk
in Fig. 1B). Again we found some RA synovium proteins
reacting with antibodies at the high molecular weight (Fig.
1C) but failed to identify them.
Protein analysis using antibody cross-linked chromatog-
raphy 
Due to the technical limitation for identification of auto-
antigens using 2-DE gel western blot as above-mentioned,
we tried another approach to isolate proteins binding to RA-
antibodies. Antibody-affinity purification is generally used
for isolation of proteins that can interact with antibody. First,
antibodies purified from RA patients were cross-linked to
Sepharose resins using CNBr-activation. Then, whole cellu-
lar proteins solubilized from tissues (OA or RA) were mixed
with antibody-bound beads. Antibody-bound proteins were
analyzed by SDS-PAGE. As shown in Fig. 2A, several high
molecular weight proteins were specifically bound to antibody
beads (lane 1-4) but not to beads without antibody cross-link
(lane C), suggesting that these are antibody-specific proteins.
Some of these proteins have been identified using mass spec-
trometry. One of them was fibronectin, a connective tissue
protein. 
Identification of proteins bound to antibodies in the syn-
ovial fluid
Some antibodies in synovial fluid might be already bound
to soluble antigen molecules. If these antigen-antibody com-
plexes can be isolated, we can identify proteins being associ-
ated with antibody in rheumatoid synovial fluids. Synovial
fluids containing antigen-antibody complexes were directly
applied to Protein A resins, and antigen-antibody complex-
es were solubilized in SDS-sample buffer rather than eluted
by low pH buffer after extensive wash in order to remove non-
specific proteins or proteins with low affinity. The bound pro-
teins were separated by a SDS-PAGE and each protein was
identified by MALDI-TOF mass spectrometry. As shown in
Fig. 2B, several proteins were bound to antibodies in synovial
fluids (indicated by lane B). They were fibronectin, semaphorin
7A (CD108), nucleoside triphosphate phosphorylase 1, growth
factor receptor binding protein 7 (GRB7), and  heavy chain
of immunoglobulin. They all were similarly found in most
RA synovial fluids (data not shown). These proteins were dis-
sociated from antibodies during the elution with low pH gly-
cine buffer as shown in Fig. 2B (indicated by lane E).
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Fig. 1. Purification of autoantibodies and blotting. (A) Antibody purification. Antibodies were purified from RA patients’ synovial fluid using
protein A affinity chromatography as described in “Materials and Methods”. Two samples of antibody (each 10  g) was analyzed by 12.5%
SDS-PAGE. Lane 1 is protein size marker. H and L indicate heavy chain and light chain of immunoglobulins, respectively. (B) Blotting on
a one-dimensional gel. Total cellular proteins (20  g each lane) derived from RA synovium tissue (63/M) were separated on a 12.5% SDS-
gel electrophoresis. They were subsequently transferred to the nitrocellulose membrane. Eight different primary antibodies isolated from
RA patients (1:500 in 5% skim milk/TBST) were incubated with the membrane for 2 hr at room temperature using multi-channel blotting
system (Bio-RAD). Secondary antibody, rabbit anti-human IgG HRP (1:2,000 in 5% skim milk/TBST), was incubated with membrane at
room temperature for 1 hr. Proteins were visualized by a ECL developing system. (C) Blotting on a two-dimensional gel. Total proteins 150
g from the RA synovium protein (63/M) was separated on a 7 cm and pH3-10 IPG strip, in the first dimension and 12.5% SDS-PAGE at
the second dimension and subsequently transferred to the nitrocellulose membrane. Primary antibody from a RA patient (40/F) (1:100 in
5% skim milk/TBST) and subsequent HRP-conjugated rabbit anti-human IgGs (1:1,000 in 5% skim milk/TBST) were incubated with the mem-
brane. Proteins were visualized by a ECL detecting system.
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Comparison of OA and RA synovium proteins
In order to isolate RA-specific synovium proteins, we first
solubilized total proteins from RA patient’s synovium and
compared them with ones obtained from OA patients, as a
control, in two-dimensional gel electrophoresis. Proteomic
analysis has several drawbacks in experimental repeatability
and statistical significance of data when in particular few sam-
ples are used for analysis. To minimize these experimental
errors, we created a reference set, as a control, from five OA
synovium samples composed of different sex and age and ma-
tched it with those from RA synovium of three different pa-
tients (Fig. 3). From these comparative analyses, we found that
about 200 proteins were 3-fold more overexpressed in RA; and
more than 100 proteins showed their expression to be decrea-
sed in RA. Some of these proteins were directly compared in
the gel (Fig. 4). Proteins (#0204, 0212, 4008, 5001, 6003,
7001) dominantly expressed in RA have been identified by
mass spectrometry and database search. They are tropomyosin
chain, fatty acid binding protein (adipocyte lipid binding
protein), peroxiredoxin 2, galectin 1, and apolipoprotein A1
precursor (Table 1). Most of these proteins have been implicat-
ed to play some roles in RA pathogenesis. More details will
be discussed. In addition, we examined total protein expres-
sion in synoviocytes sub-cultured from RA and OA synovi-
um tissues using two-dimensional gel electrophoresis. Many
proteins showed also their differential expression between OA
and RA primary synoviocytes sub-cultured from each patient.
In particular, a skeletal protein vimentin was much more
highly overexpressed in OA than RA (data not shown).
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Fig. 2. Isolation of autoantogens. (A) Affinity purification of autoantigens. Four different purified IgGs coupled to CNBr-activated Sepharose
4B were incubated with total synovial proteins for 1 hr at room temperature. After wash with binding buffer three times, one bead volume of
2X SDS sample buffer was added to protein-bound resins. After boiling for 5 min, the supernatant was separated on a 10% SDS-PAGE. C
is a control, no cross-linked antibody. M indicates protein size marker. (B) Analysis of antigen-antibody complexes in synovial fluids. Syn-
ovial fluid (RA patients #14 and 19) was incubated with protein A resins. After washing protein A bead with 10 mM Tris-HCl (pH 7.5), beads
were mixed with one bead volume of 2X SDS sample buffer and boiled for 7 min. The solubilized proteins were separated by a 10% SDS-
PAGE after centrifugation at 13,000 rpm for 5 min and visualized by Coomassie blue staining. The specific proteins were identified by MA-
LDI-TOF mass spectrometry as described (8-10). Lane B indicates antibody-antigen mix isolated and solubilized by SDS-sample buffer,
and lane E is antibody sample eluted by low pH buffer as described in antibody purification.
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Fig. 3. An OA reference set for RA protein comparison. Total OA
synovium proteins (40  g) were separated on a two-dimensional
gel: a linear IPG strip 17 cm and pH 4-7 at the first dimension and a
7.5-17.5% gradient SDS-PAGE at the second dimension. Protein
spots were detected by silver staining. Five OA gels were matched
together to create a reference set using the PDQuest program. This
reference set was used for comparison with RA gels. Numbers in
parentheses indicate age of patients.482 C.W. Kim, E.H. Cho, Y.J. Lee, et al.
DISCUSSION
Rheumatoid arthritis, an autoimmune disease with chronic
inflammation and destruction of cartilage and bone, has a
prevalence of 1% over the world. Recently, the research in
cytokines has provided some critical insights about their role
in the RA development, but the immunological identities
causing autoimmunity in RA pathogenesis are not clear (11,
12). To date, several candidates for autoantigen that might
involve in occurrence of RA have been identified. For exam-
ples, type II collagen, glucose-6-phosphate isomerase, human
cartilage protein gp39, and chaperone protein BiP have been
isolated and studied for their roles in RA. In particular, the
mouse injected by type II collagen showed the development
of arthritis, relatively similar to RA (5). Also, antibodies react-
ing with collagen have been found in the synovial fluids of
RA patients. However, only 25-45% of RA patients contain
anti-collagen antibodies, and even these patients have differ-
ent epitopes of collagen, suggesting that antibody produc-
tion against collagen might be the secondary consequence
of RA induction (7). Human cartilage protein gp39, a gly-
coprotein, is specifically expressed in synoviocytes of some
Protein spots were isolated from the gel and identified by peptide mass
fingerprinting using MALDI-TOF mass spectrometry as described previ-
ously (8, 9).
Spot Protein  Mass  MOWSE  MW  Accession 
number identified matched (%) score (kDa)/pI number
5001 Galectin-1 20 6.0×10
3 14/5.3 P09382
6003 Peroxiredoxin 2 34 1.3×10
3 21.8/5.7 P32119
4009 Apo-A1 precursor 37 3.4×10
8 31/5.6 P02647
7001 Fatty acid  18 1.5×10
6 14.7/6.6 P15090
binding protein
0212 Tropomyosin 44 450 32/4.7 P09493
chain
0204 Tropomyosin 44 7.3×10
5 32/4.7 P07951
chain
Table 1. Mass spectrometry analysis of isolated protein spots
OA
RA
Fig. 4. Comparison of RA and OA proteins. Total RA or OA synovium proteins (40  g) were separated on a two-dimensional gel: a linear
IPG strip 17 cm and pH 4-7 at the first dimension and a 7.5-17.5% gradient SDS-PAGE at the second dimension. The RA gel was matched
with the OA reference set (Fig. 3), and the relative values in (B) were obtained from the PDQuest analysis as described (8). The spot numbers
were randomly given by the program.
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RA patients and sometimes found in synovial fluid (13). Fur-
thermore, this protein binds to DR4 that have been consid-
ered as RA-specific haplotype. However, according to a recent
paper, main CD4+ lymphocytes existing at the connective
tissues of RA patients were not specific to gp39 protein (14).
Antibody against glucose 6-phosphate isomerase has been
found in RA patients and also in K/BxN mice developed RA-
like arthritis by serum transfer (6, 15). But it is still not clear
how this protein involves in RA pathogenesis. Besides, aggre-
can, a component of cartilage, and epithelial filaggrin have
been determined as autoantigen (16, 17). In addition, endo-
plasmic reticulum chaperone protein BiP is strongly express-
ed in the lining cells of RA synovium, and BiP stimulates T
lymphocyte proliferation. Anti-BiP antibodies have been
found in many RA patients (63%) (18, 19).
In this report we tried to isolate RA-specific proteins using
antibody-antigen interaction and proteomic approach. About
5 mg/mL antibodies present in the synovial fluid of RA pa-
tients. Some molecules bound to these antibodies were high
molecular weight proteins such as fibronectin, nucleoside
triphosphate phosphorylase 1, semaphorin 7A precursor, and
growth factor receptor-bound protein 7. In particular, fibro-
nectin has been previously suggested as an autoantigen for
RA (20, 21). It is a glycoprotein that is typically expressed
on the surface of fibroblasts. A major function of the fibro-
nectin is cell adhesion to the extracellular matrix or cell-cell
contact. Also, fibronectin stimulates endocytosis and promotes
the clearance of particular materials from the circulation (22).
Therefore, production of antibody against fibronectin might
cause cell destruction typically appearing during the RA pa-
thogenesis.  
Currently, many techniques to massively detect the differ-
ential expression of genes between normal and malignant state
have been developed. Here we applied proteomic approach to
isolate some RA-specific proteins by comparing RA patient’s
synovium with OA patient’s one in a two-dimensional gel.
Because acquisition of synovial tissues from normal person is
limited, we used OA patient’s synovium as a control. Many
proteins were differentially expressed between RA and OA.
Among them, vimentin was dominantly expressed in OA
cultured-synoviocytes but its expression in RA cultured-syn-
oviocytes was severely suppressed, suggesting that down-reg-
ulation of vimentin might play a role in RA pathology. Vi-
mentin, an intermediate filament protein normally expressed
in cells of mesenchymal origin, plays several roles in many
biological reactions (23). For the most part, vimentin expres-
sion coincides with cellular growth and is cell-cycle-regulat-
ed (24). In addition, vimentin expression can contribute to
the augmentation of motility and invasiveness in some can-
cers (25). Moreover, it has been suggested that vimentin can
act as a signal transducer, relaying information from the extra-
cellular matrix to the nucleus (26). Due to its diverse function,
down-regulation in RA might cause some pathogenic phe-
notypes. 
In this study, tropomyosin, adipocyte lipid binding protein,
peroxiredoxin 2 (thioredoxin peroxidase 1), galectin-1 (beta -
galactoside-binding lectin L-14-1), and apolipoprotein A-1
precursor (Apo-A1) were over-expressed in RA. These pro-
teins have been previously suggested to play some roles in
RA. Galectin-1 revealed a diverse range of activities in rela-
tion to cell survival and proliferation. Expression of galectin-
1 was down-regulated in juvenile idiopathic arthritis charac-
terized by hyperplasia of synovial cells, and galectin-3 was
over-expressed (27). Also, galectin-3 expression was elevated
in RA sera and synovial fluids (28). Antibody against perox-
iredoxin 2, an anti-oxidative protein, has been detected in se-
veral systemic autoimmune diseases such RA or lupus erythe-
matosus. In particular, peroxiredoxin 2 antibody has been ob-
served in 19% of RA patients (29). Cytokines such as TNF-
and IL-1 have been implicated in pathogenesis of RA. Pro-
duction of these cytokines was blocked by apolipoprotein-A1,
and level of this protein was highly elevated in the synovial
fluid of RA patients (30, 31). In addition, tropomyosin anti-
bodies have been observed in RA patients, suggesting that
there are some correlation between muscular proteins and RA
activity (32). According to a recent proteome analysis using
synovial fluid and serum of patients with RA, calgranulin A,
B, C proteins were highly elevated in erosive RA patients (33).
Taken together, most proteins isolated from this comparative
analysis of three RA synovial tissues and an OA match set are
likely associated with a number of metabolic alterations lead-
ing to inflammatory arthritis although further analyses are
required to make a solid conclusion.
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